GUILFORD, Conn.–(BUSINESS WIRE<\/a>)–Hyperfine, Inc.<\/a> (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain\u2014the Swoop\u00ae system\u2014 today announced that Hyperfine is expected to join the broad-market Russell 3000\u00ae Index and the small-cap Russell 2000\u00ae Index at the conclusion of the June 2026 Russell Reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Hyperfine’s inclusion will become effective after the U.S. market close on June 26, 2026.<\/p>\n \nThe June reconstitution of the Russell US indexes captures up to the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000\u00ae Index, which remains in place for six months under the semi-annual reconstitution schedule beginning in 2026, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.<\/p>\n \n\u201cWe are pleased that Hyperfine is expected to join the Russell 3000 and Russell 2000 Indexes as part of the June 2026 reconstitution,\u201d said Maria Sainz, President and Chief Executive Officer of Hyperfine. \u201cWe believe this inclusion reflects the continued progress in executing our commercial strategy, broadening awareness and driving adoption of our portable MRI technology and creating long-term value for shareholders.\u201d<\/p>\n \nRussell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2025, about $12.2 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.<\/p>\n About the Swoop\u00ae Portable MRI Systems About Hyperfine, Inc. \nHyperfine, the Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine.<\/p>\n Forward-Looking Statements View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260526952799\/en\/<\/a><\/span><\/p>\n Media Contact Investor Contact KEYWORDS:<\/b> Connecticut United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Technology Medical Devices Neurology Health Technology Software Radiology Health General Health Artificial Intelligence<\/p>\n
\n
<\/b>The Swoop\u00ae Portable MR Imaging\u00ae Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.<\/p>\n
\n
<\/b>Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop\u00ae system\u2014the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop\u00ae system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com<\/a>.<\/p>\n
\n
<\/b>This press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the \u201cCompany\u201d) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company\u2019s goals and commercial plans, the benefits of the Company\u2019s products and services, and the Company\u2019s future performance and its ability to implement its strategy, including its entrance into new markets. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company\u2019s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company\u2019s product development and commercialization activities, including the degree that the Swoop\u00ae<\/i> system is accepted and used by healthcare professionals; the Company\u2019s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to progress on product advancements and improvements; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company\u2019s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company\u2019s products and services and reimbursement for medical procedures conducted using the Company\u2019s products and services; existing and potential future National Institutes of Health funding pressures; existing and potential future effects from U.S. export controls and tariffs; the Company\u2019s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company\u2019s financial performance; and other risks and uncertainties indicated from time to time in the Company\u2019s filings with the Securities and Exchange Commission, including those under \u201cRisk Factors\u201d therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.<\/p>\n<\/p>\n
\n
<\/b>Devin Zell
\n
Hyperfine
\n
dzell@hyperfine.io
\n<\/a><\/p>\n
\n
<\/b>Webb Campbell
\n
Gilmartin Group LLC
\n
webb@gilmartinir.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260526952799\/en\/2375273\/3\/Hyperfine_Logomark_Full_Color_RGB_600px_tall.jpg\")
<\/td>\n<\/tr>\n